

# PROVIDER ALERT

## CHANGES TO PRIOR AUTHORIZATION REQUIREMENTS FOR SELECT OUTPATIENT MEDICAL INJECTIONS

Effective September 1, 2019, there will be new prior authorization (PA) requirements for several outpatient medical injectables. This change impacts all members of University of Maryland Medical System Health Plans – University of Maryland Health Partners (Maryland Medicaid) and University of Maryland Health Advantage (Medicare Advantage).

The new PA requirements are specific for submitted claims that include the J-Codes listed below with a date of service of 09/01/2019 and after.\*

- J9271 – Keytruda (pembrolizumab)
- J9299 – Opdivo (nivolumab)
- J9355 – Herceptin (trastuzumab)
- J9145 – Darzalex (daratumumab)

**Important:** Please see billing cheat sheet below for J-Code unit conversions

J-Code	Billing Unit Conversion
J9271 (Keytruda)	1mg = 1 unit
J9299 (Opdivo)	1mg = 1 unit
J9355 (Herceptin)	10mg = 1 unit
J9145 (Darzalex)	10mg = 1 unit

\*A PA is not required for the associated administration/codes related to the infusion of these outpatient medical injectables. Also, this new PA requirement **does not change the existing home infusion PA requirement** that would be submitted along with these J-Codes.

Authorization forms and guidelines can be found by visiting:

- Univ of Maryland Health Advantage  
[www.ummedicareadvantage.com](http://www.ummedicareadvantage.com)
- Univ of Maryland Health Partners  
[www.umhealthpartners.com](http://www.umhealthpartners.com)

If you have any questions, please contact Provider Relations at 410-779-9359 or 800-730-8543 for additional explanation or guidance.